Veena Dubal interviews Aziza Ahmed about the exclusion of women from early AIDS definitions, the feminist lawyers and activists who transformed the government’s response to the epidemic, and the adverse public health consequences of carceral feminism.
A decade ago, Martin Shkreli became the most hated man in America by raising the price of Daraprim – an antiparasitic essential for immunocompromised patients – from $17.50 to $750 per pill. Though Shkreli’s conduct was lambasted in the court of public opinion, the legal framework that allowed this 4,000 percent increase remains in place. And Daraprim? It still costs $750 a pill.
While many industries excel at not paying U.S. corporate taxes, the pharmaceutical industry takes the cake – despite $400 billion in prescription drug sales in 2022, Big Pharma claimed to have close to zero taxable income. One of their principal methods for maintaining this charade is the constant threat of exit, moving their headquarters abroad to avoid U.S. taxes altogether. In order to collect more much needed tax revenue from corporations, policymakers must first constrain Big Pharma’s ability to simply abandon ship.
As Republicans tightened work requirements and eligibility rules for Medicaid and SNAP last year, Equifax’s CEO openly celebrated the profits to be made from administering this deprivation. Means-testing and administrative complexity have turned America’s safety net into a lucrative revenue stream for monopolistic private contractors, underscoring the need for public data infrastructure and simpler eligibility rules.
As hospice care is increasingly dominated by private equity firms, an antitrust response, while necessary, has the potential to normalize the language of the market as the default mode for discussing healthcare reform. Hospice demonstrates what is lost when healthcare is described as a mere economic exchange, and Medicare’s per diem hospice benefit harbors as-yet-unrealized potential for decommodification.
Powerful health care companies shape the informational environments around their products. As part of this playbook, companies avoid or thwart the generation and dissemination of accurate information on the true value of their products. Consequently, Americans spend too much on health care with dubious or even negative value.
Though heralded as a policy innovation, value-based payment has not succeeded in lowering costs and has instead fueled corporate consolidation, as many physicians are ill-equipped to assume the financial risk that the payment model requires. Embodying the core tenets of neoliberalism, VBP is ultimately a failure of policymakers to equitably and efficiently administer a public health care program.
For the half-million people in the U.S. with kidney failure, survival rests in the hands of two powerful corporations — DaVita and Fresenius — that control over 70% of the outpatient dialysis market. But the history of dialysis isn’t a simple narrative of corporate consolidation; it’s a case study of how public funding can entrench private power in health care.
Private equity firms are acquiring dominant shares of physician practices, creating conflicts between shareholder value and physicians’ professional and ethical duties. While longstanding state laws that prohibit lay ownership of medical practices have been under-enforced and evaded, recent litigation and legislative proposals suggest they could be revitalized to address today’s forms of corporatization.
From the dialysis market to the pharmaceutical industry, health care is seeing growing consolidation and corporatization. Over the next month, this symposium will explore the financialization of various health care industries and begin to sketch the contours of a progressive pushback—how law, policy, and regulatory action can help erect guardrails to protect us from both illness and insolvency.
New Uber-style firms like CareRev and Clipboard Health use algorithmic scheduling, staffing, and management technologies to match understaffed medical facilities with nearby nurses and nursing assistants looking for work. These companies, while promising flexibility, are facilitating a race to the bottom among healthcare workers and contributing to the erosion of America’s already-strained health care system.
With summer just around the corner, are you looking to indulge in some juicy, page-turning scholarship? As always, the Blog has you covered with our biannual roundup of some of our favorite forthcoming LPE and LPE-adjacent articles.
The persecution of transgender people, though often treated as a niche concern, is central to today’s political and economic realignments. These attacks are not ancillary but entangled with broader efforts to reassert control over race, gender, and migration.
The Trump Administration’s anti-trans policies should be seen as central, rather than peripheral, to the creation of what Melinda Cooper has called “an anti-social state” — a state that would abandon every duty to serve its citizens and residents, whose sole purpose would be to amplify presidential executive power.
The Manhattan Institute’s obsessive focus on trans medicine is a part of its broader effort to erode public trust in medical professionals and federal health authorities.
